Zhejiang Cheng Yi Pharmaceutical Co., Ltd. (SHA:603811)

SHA:603811 Revenue

Zhejiang Cheng Yi Pharmaceutical had revenue of 182.40M CNY in the quarter ending September 30, 2026, with 1.13% growth. This brings the company's total for the last twelve months to 829.51M, up 4.89% year-over-year. In the year 2025, Zhejiang Cheng Yi Pharmaceutical had annual revenue of 812.35M with 13.72% growth. That makes Zhejiang Cheng Yi Pharmaceutical the 21,059th largest company in the world by revenue and 3,863rd in China.

• Revenue (ttm): 829.51M
• Revenue Growth: +4.89%
• P/S Ratio: 3.50
• Revenue / Employee: 1.37M
• Employees: 604
• Market Cap: 2.90B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Preparations 687.69M 84.8%
• Active Pharmaceutical Ingredient (API) 115.47M 14.2%
• Food 3.25M 0.4%
• Intermediates and Others 2.70M 0.3%
• Traditional Chinese Medicine 1.76M 0.2%

By Geography

Chart

• China 789.74M 97.4%
• Overseas 21.13M 2.6%

Fiscal year ended Dec 31, 2025 See the full SHA:603811 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	812.35M	97.98M	13.72%
Dec 31, 2024	714.37M	42.74M	6.36%
Dec 31, 2023	671.63M	16.65M	2.54%
Dec 31, 2022	654.97M	-38.99M	-5.62%
Dec 31, 2021	693.96M	-64.17M	-8.46%

Data Source: S&P Global Market Intelligence Last updated: Oct 28, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 9, 2026

Data Sources Report a data error